Braintree Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRAINTREE, and when can generic versions of BRAINTREE drugs launch?
BRAINTREE has nine approved drugs.
There are five US patents protecting BRAINTREE drugs.
Drugs and US Patents for Braintree
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Braintree | GOLYTELY | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous | FOR SOLUTION;ORAL | 019011-001 | Jul 13, 1984 | AA | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Braintree | NULYTELY-FLAVORED | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION;ORAL | 019797-002 | Nov 18, 1994 | AA | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Braintree Labs | SUTAB | magnesium sulfate; potassium chloride; sodium sulfate | TABLET;ORAL | 213135-001 | Nov 10, 2020 | RX | Yes | Yes | 10,143,656 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Braintree
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Braintree Labs | SUPREP BOWEL PREP KIT | magnesium sulfate; potassium sulfate; sodium sulfate | SOLUTION;ORAL | 022372-001 | Aug 5, 2010 | 6,946,149 | ⤷ Try a Trial |
Braintree | HALFLYTELY | bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL | 021551-003 | Jul 16, 2010 | 7,291,324 | ⤷ Try a Trial |
Braintree | AXID | nizatidine | SOLUTION;ORAL | 021494-001 | May 25, 2004 | 6,930,119 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRAINTREE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Oral Solution and Delayed- | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg | ➤ Subscribe | 2008-01-28 |
➤ Subscribe | Oral Solution | 15 mg/mL | ➤ Subscribe | 2008-05-14 |
➤ Subscribe | For Oral Solution and Delayed-release Tablet | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen) | ➤ Subscribe | 2010-07-30 |
➤ Subscribe | Oral Solution | 17.5 g/3.13 g/1.6 g per bottle | ➤ Subscribe | 2010-11-08 |
Similar Applicant Names
Here is a list of applicants with similar names.